Name (Synonyms) | Correlation | |
---|---|---|
drug363 | Hydroxychloroquine + Placebo Wiki | 1.00 |
drug349 | High-Titer COVID-19 Convalescent Plasma (HT-CCP) Wiki | 1.00 |
drug362 | Hydroxychloroquine + Azithromycin Wiki | 1.00 |
drug618 | Placebo + Placebo Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.12 |
D007239 | Infection NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS.
Description: The primary outcome will be the MOS numerical score (score 0-9) where a score of 0 attributes to 'no clinical evidence of infection' and a score of 9 attributes to 'death'. The eligibility requirements for this trial select individuals at level 3 or higher on the modified scale, but the day 14 outcome can be any one of 10 levels.
Measure: Modified WHO Ordinal Scale (MOS) score Time: Day 14